Alexander O. Schuth Sells 7,500 Shares of Denali Therapeutics Inc (NASDAQ:DNLI) Stock
Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $20.28, for a total value of $152,100.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
NASDAQ:DNLI opened at $20.22 on Friday. The stock’s 50 day moving average price is $20.00. The company has a current ratio of 11.55, a quick ratio of 11.55 and a debt-to-equity ratio of 0.14. Denali Therapeutics Inc has a 52-week low of $12.32 and a 52-week high of $28.86.
Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). The firm had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $12.88 million. Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. On average, research analysts expect that Denali Therapeutics Inc will post -1.54 EPS for the current fiscal year.
DNLI has been the topic of a number of research reports. ValuEngine upgraded WPP from a “sell” rating to a “hold” rating in a research note on Wednesday, June 19th. Zacks Investment Research downgraded EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. TheStreet upgraded SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a research note on Thursday, June 13th. Finally, HC Wainwright restated a “buy” rating on shares of ACASTI PHARM-TS in a research note on Wednesday, June 26th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $25.50.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Recommended Story: Yield Curve
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.